(Q34903258)

English

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

peritoneal carcinomatosis

1 reference

based on heuristic

inferred from title

Isabelle Navarro-Teulon

13

object named as

Isabelle Navarro-Teulon

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Vincent Boudousq

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Laure Bobyk

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Muriel Busson

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Véronique Garambois

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Marta Jarlier

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Paraskevi Charalambatou

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

André Pèlegrin

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Salomé Paillas

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Nicolas Chouin

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

François Quenet

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Patrick Maquaire

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Julien Torgue

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jean-Pierre Pouget

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

29 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

e69613

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

copyright license

Creative Commons Attribution 4.0 International

29 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Clinical radioimmunotherapy--the role of radiobiology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Cancer radioimmunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Biodistribution of 211At-labeled humanized monoclonal antibody A33.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Radioimmunotherapy and colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

8 July 2018

Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0069613

21 January 2018

Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

26 October 2018

Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3726680

26 October 2018

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antigenic sites in carcinoembryonic antigen

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved in vivo stability and tumor targeting of bismuth-labeled antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is intraperitoneal chemotherapy after cytoreductive surgery efficient? Knowing whether it is or not appears secondary!

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

1 reference

https://pubmed.ncbi.nlm.nih.gov/23922757

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0069613

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2013PLoSO...869613B

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34903258&oldid=1864325660"